3-Amino-2-Hydroxy Acetophenone

70977-72-9

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is marke∑t-oriented and realizes industrial development through R&D innovatio¶n and technology transformation.

key word:

innovative Pharmaceutical

Category:

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a larg¶e health industry finance platform company integrating pharmaceutical, intelligent medical, b♠io pharmaceutical R&D, industrial production and sales.

The chemical reactions involved in the existing products include Foucault reactio↕n, nitration reaction, sulfonation reaction, hydrogenation reaction, fluorination reac>tion, chlorination reaction, bromination reaction, diazotization reaction, format >reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor developed by Mercαk. In October 2006, Sitagliptin phosphate Januvia was approved by FDA as the first DPP4ε inhibitor for the treatment of type ⅱ diabetes mellitus. The characteristics ↓of this drug are that it can stimulate insulin secretion wh ile reducing hunger without causing weight gain. Hypoglycemia and edema will not occur≤, and it is suitable for diabetic patients with poor blood glucose control and frequent h™ypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech phar maceutical enterprise that is market-oriented and realizes industria€l development through R&D innovation and technology transform$ation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one ≥of the most important products for the treatment of arthritis. It is well toler®ated and has a low incidence of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major ¥leukotriene receptor antagonists. In clinical application, it has good the​rapeutic effect on atopic asthma and other types of bronchial asthma, and the market prospect is✘ huge. In the major category of asthma drugs, leukotriene receptσor antagonists have the fastest growing market sha≥re.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical ente€rprise that is market-oriented and realizes industrial deδvelopment through R&D innovation and technology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the second drug approved by FDA f₩or Alzheimer's disease in the United States. Its treatment reaches the targeσt dose and has low toxic and side effects. It has bδeen widely recognized by our medical community, and good tolerance is its biggest advantage. In Oc£tober 1999, Donepezil was launched in China under tπhe trade name "Aricept", which is the main chemical drug against Alzheimer's di>sease. At present, CFDA has approved a number of dome©stic enterprises to produce donepezil preparations, the main dosage forms are tablets♠, capsules, dispersive tablets, oral disintegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-Myers Squibb/Pfizer)&, a direct oral factor Xa inhibitor, was approved for use in the 27 ‌EU member states. The world's first drug approved to prevenφt venous thromboembolism (VTE) in adult patients unde'rgoing elective hip or knee replacement. From June 2019 to June 2020, the annual sales of apix¥aban products overseas reached about $15.4 billion, with a year-on-year growth of nearly ±32%, and the API consumption reached about 23,960 kg, with a year-on-year growth of λabout 28%. Compared with its main competitor, Rivaroxaban, the ™drug's annual overseas sales are about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceuticalγ enterprise that is market-oriented and realizes industrial devel∑opment through R&D innovation and technology transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manu♣factured by Genzyme. On December 29, 2004, it was approved by FDA for the• treatment of refractory or relapsed acute lymphoblastic leukemia (ALL)≠ in children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pha¥rmaceutical enterprise that is market-oriented and realizes industrial development through Rπ&D innovation and technology transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). If you need other serv ices, E-mail: 2880705932@qq.com
Submit